Galectin Therapeutics Video Library

CEO Joel Lewis on his vision and goals for Galectin Therapeutic

…I had two requests when Kevin Freeman and Dick Uihlein asked me to be the CEO. One was that we find a world-class Chief Medical Officer, because I’m not a scientist, so I’m a business guy, and we absolutely found one in Pol [Boudes]. And then my next request…. [was] that 80% of my compensation be paid in stock. I felt like my goals and my success should be aligned with shareholders… As a business guy, I wish more CEOs would take that approach.

Dr. Ben Carson on the potential behind Galectin Therapeutics

…that caused me to start looking into [the science behind Galectin Therapeutics], and really seeing that some of the possibilities of being able to inhibit things like the deleterious protein complex like galectin-3, which is significant in so many types of pathologies….  And it seemed like it was something that people really weren’t paying a lot of attention to, even though it potentially impacts tens of millions of people.

Galectin Therapeutics Leadership Discussion with Dr. Ben Carson (edited)

Galectin Therapeutics’ leadership team and Board of Directors discuss the goals and next innovations for the company with Senior Advisor, Dr. Ben Carson. Left to right, Kevin Freeman, Vice Chairman of the Board of Directors; Dr. Ben Carson, Senior Advisor to Galectin Therapeutics; Joel Lewis, Chief Executive Officer and President; Dick Uihlein, Chairman of the Board of Directors; Dr. Pol Boudes, Chief Medical Officer; and Rick Zordani, Audit Committee Chairman, Board of Directors

Dr. Ben Carson: To me it’s just exciting to be able to work with such a talented group…. [in] something that has such broad potential applications — you know galectin-3 and the whole family of galectins affect almost every organ system.

Kevin Freeman: People call me and say, “Hey, we’ve got such and such a company. How in the world do you have Dick Uihlein as your chairman?” For as small as we are, with the great potential that we have, the answer I think is we have exciting science, we have an incredible team, and we have a great business.

Joel Lewis: This is very exciting for me. Part of what’s great about working with all of you is I know how committed everybody is to try to find those partners, [which is] not easy for a small biotech to do…. Pol and I are changing how the company’s been run. We really are positioning ourselves to be much more enticing to large pharma. Pol’s operating our company as a drug developer should.

Dr. Pol Boudes: You know what you have to do to put the drug on the market, so you have to be laser focused on that.

Dick Uihlein: We all believe in this, and we know we’re going to be successful…. To watch what has been happening is truly, truly exciting, and I hope that everybody gets to our website and really studies and reads up and maybe gets to see… Dr. Carson, your interview, and [Dr. Boudes, yours too][N.B., not yet posted], because then you get a real understanding of why this is so important and what is about to happen.

CMO Dr. Pol Boudes on the innovation behind Galectin Therapeutics NASH cirrhosis clinical trial

…I like to do things that have not been done before. And that’s exactly what we are doing, and I like also to do things [that benefit] patients…. We’re trying to solve a problem that has never been solved before, and in that case it’s a liver disease and it’s cirrhosis, and it’s been a neglected field for a long, long time.

Galectin Therapeutics Leadership Discussion with Dr. Ben Carson (full interview)

This video is the full conversation used to create the edited version above.

Part 1

Part 2